| Similar Articles |
|---|
 |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.   |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
October 11, 2010
Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
May 29, 2009
Brian Orelli |
This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
January 13, 2010
Brian Orelli |
JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
February 23, 2009
Brian Orelli |
The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
May 31, 2011
Brian Orelli |
Too Many Drugs, Too Little Cash AVEO seals a deal with Johnson & Johnson. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
June 19, 2009
Brian Orelli |
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
The Motley Fool
November 11, 2010
Brian Orelli |
Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
July 16, 2009
Brian Orelli |
Keep Your Chin Up, J&J An FDA advisory committee smacked down its drug candidate. |
The Motley Fool
October 31, 2008
Brian Orelli |
World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon. |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
June 30, 2009
Brian Orelli |
One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days. |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
November 22, 2010
Brian Orelli |
Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
